⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
PTGX News
Protagonist Therapeutics, Inc
Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
accessnewswire.com
PTGX
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)
businesswire.com
TAK
PTGX
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera
businesswire.com
PTGX
TAK
Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update
accessnewswire.com
PTGX